Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis.
Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis.
复制标题
DOI：
10.1007/s00296-021-04803-9
复制
发表时间：
2021-05
影响因子：
4
通讯作者：
Lu W
中科院分区：
文献类型：
--
作者：
Wang Q;Liu J;Shao R;Han X;Su C;Lu W
由于免疫功能受损，风湿病患者往往更容易感染不同的细菌和病毒，但目前尚不清楚新型冠状病毒(SARS-CoV-2)是否有更高的感染风险和更严重的病程。我们进行了这项系统回顾和荟萃分析，以评估与普通人群相比，风湿病患者服用新冠肺炎的风险和临床结果。计算机检索PubMed、EMbase、Scope us和Web of Science数据库2020年1月1日至2020年10月20日，以确定与风湿病患者和新冠肺炎相关的流行病学信息，包括明确的风险估计或可转换和提取的数据。我们纳入26项观察性研究，总计约2000名风湿病患者，其中新冠肺炎感染。Meta分析显示，风湿病患者新冠肺炎感染的风险显著高于普通人群(OR = 1.53，95%CI 1.24~1.88，P = 0.000)。在住院和与新冠肺炎相关的严重临床结局方面，我们发现风湿病患者与参考人群表现出相似的结果(住院OR = 1.36，95%CI 0.81~2.29，P = 0.247；进入ICU OR = 1.94，95%CI 0.88~4.27，P = 0.098；死亡OR = 1.29，95%CI 0.84~1.97，P = 0.248)。合并高血压、肺部疾病与风湿病患者新冠肺炎相关住院风险增加显著相关，抗肿瘤坏死因子药物与较低住院风险相关。年龄越大，新冠肺炎越重。我们的荟萃分析表明，风湿病患者感染新冠肺炎的风险更高，但可能不会导致更严重的疾病进程。网上版载有补充材料，可在10.1007/s00296-021-04803-9查阅。
Patients with rheumatic diseases are often more susceptible to different bacteria and viruses because of immune impairment, but it is not clear whether there is a higher risk of infection and a more serious course of disease for novel coronavirus (SARS-CoV-2). We performed this systematic review and meta analysis to assess the risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population. We searched PubMed, EMBASE, Scopus and Web of Science databases from January 1, 2020 to October 20, 2020 to determine epidemiological information related to patients with rheumatic diseases and COVID-19, including clear risk estimate or data that could be converted and extracted. We included 26 observational studies, totaling about 2000 patients with rheumatic diseases of whom were infected with COVID-19. Meta-analysis showed that the risk of COVID-19 infection in rheumatic patients was significantly higher than that in the general population (OR = 1.53, 95% CI 1.24–1.88, P = 0.000). In terms of hospitalization and severe clinical outcomes associated with COVID-19, we found that rheumatic patients showed similar results to the reference population (hospitalization OR = 1.36, 95% CI 0.81–2.29, P = 0.247; admitted to ICU OR = 1.94, 95% CI 0.88–4.27, P = 0.098; death OR = 1.29, 95% CI 0.84–1.97, P = 0.248). The presence of comorbidities, hypertension, lung diseases were significantly associated with the increased risk of COVID-19-related hospitalization in rheumatic patients and anti-TNF drugs were associated with lower hospitalization risk. Older age was related to severe COVID-19. Our meta-analysis indicated that rheumatic patients were at a higher risk of COVID-19 infection but might not lead to a more serious disease process. The online version contains supplementary material available at 10.1007/s00296-021-04803-9.
登录
查看更多内容
DOI：
10.1002/art.41450
发表时间：
2020-12
期刊：
Arthritis & rheumatology (Hoboken, N.J.)
影响因子：
--
作者：
Fernandez-Ruiz R;Masson M;Kim MY;Myers B;Haberman RH;Castillo R;Scher JU;Guttmann A;Carlucci PM;Deonaraine KK;Golpanian M;Robins K;Chang M;Belmont HM;Buyon JP;Blazer AD;Saxena A;Izmirly PM;NYU WARCOV Investigators
通讯作者：
NYU WARCOV Investigators
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
11.1
作者：
Lechien, Jerome R.;Chiesa-Estomba, Carlos M.;Saussez, Sven
通讯作者：
Saussez, Sven
影响因子：
13.3
作者：
Favalli, Ennio Giulio;Monti, Sara;Montecucco, Carlomaurizio
通讯作者：
Montecucco, Carlomaurizio
影响因子：
105.7
作者：
Higgins, JPT;Thompson, SG;Altman, DG
通讯作者：
Altman, DG